162 related articles for article (PubMed ID: 38693813)
1. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract][Full Text] [Related]
2. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
3. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Naito T; Uchino J; Kojima T; Matano Y; Minato K; Tanaka K; Mizukami T; Atagi S; Higashiguchi T; Muro K; Takayama K; Furuse J; Morishima E; Takiguchi T; Tamura K
Cancer; 2022 May; 128(10):2025-2035. PubMed ID: 35195274
[TBL] [Abstract][Full Text] [Related]
5. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
6. Anamorelin in Japanese patients with cancer cachexia: an update.
Wakabayashi H; Arai H; Inui A
Curr Opin Support Palliat Care; 2023 Sep; 17(3):162-167. PubMed ID: 37389636
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.
Hamauchi S; Furuse J; Takano T; Munemoto Y; Furuya K; Baba H; Takeuchi M; Choda Y; Higashiguchi T; Naito T; Muro K; Takayama K; Oyama S; Takiguchi T; Komura N; Tamura K
Cancer; 2019 Dec; 125(23):4294-4302. PubMed ID: 31415709
[TBL] [Abstract][Full Text] [Related]
8. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
9. Anamorelin for cancer cachexia.
Nishie K; Sato S; Hanaoka M
Drugs Today (Barc); 2022 Mar; 58(3):97-104. PubMed ID: 35274629
[TBL] [Abstract][Full Text] [Related]
10. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Wakabayashi H; Arai H; Inui A
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):14-16. PubMed ID: 33382205
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia.
Takeda T; Sasaki T; Okamoto T; Ishitsuka T; Yamada M; Nakagawa H; Mie T; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Intern Med; 2023 Jul; 62(13):1887-1893. PubMed ID: 36418096
[TBL] [Abstract][Full Text] [Related]
12. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
[TBL] [Abstract][Full Text] [Related]
13. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Graf SA; Garcia JM
Drug Des Devel Ther; 2017; 11():2325-2331. PubMed ID: 28848326
[TBL] [Abstract][Full Text] [Related]
14. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ
Nakanishi Y; Higuchi J; Honda N; Komura N
Nihon Yakurigaku Zasshi; 2021; 156(6):370-381. PubMed ID: 34719572
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.
Garcia JM; Friend J; Allen S
Support Care Cancer; 2013 Jan; 21(1):129-37. PubMed ID: 22699302
[TBL] [Abstract][Full Text] [Related]
17. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Fonseca GWPD; von Haehling S
Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
[TBL] [Abstract][Full Text] [Related]
18. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Bai Y; Hu Y; Zhao Y; Yu X; Xu J; Hua Z; Zhao Z
Support Care Cancer; 2017 May; 25(5):1651-1659. PubMed ID: 28074289
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study.
Takayama K; Takiguchi T; Komura N; Naito T
Cancer Med; 2023 Feb; 12(3):2918-2928. PubMed ID: 36394148
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
Currow DC; Skipworth RJ
Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
